The Mission Report

Marcum MicroCap Conference
May 27-28, 2015 - Grand Hyatt Hotel, New York, NY

The two-day Marcum MicroCap Conference provides an opportunity for small cap equities to network with fund managers and high net worth investors. This year’s conference is expected to draw more than 2,000 participants, and features presentations by CEOs and CFOs from six principal industry sectors, expert panels moderated by industry leaders, and the chance to meet one-on-one with management of these companies.

SLOT 1 – 1pm

OncoSec Medical, Inc. (ONCS)

OncoSec Medical, Inc. (OTCQB: ONCS) is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have established an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response limiting the systemic toxicities associated with other treatments. For more information, visit the company’s website at

Perma-Fix Environmental Services, Inc. (PESI)

Perma-Fix Environmental Services, Inc. (NASDAQ: PESI), a nuclear services company, provides nuclear and mixed waste management services, including management and treatment of radioactive and mixed waste for hospitals, research labs and institutions, and federal agencies. The company operates four nuclear waste treatment facilities and provides nuclear services at the U.S. Department of Education and Department of Defense, and other commercial nuclear facilities nationwide. For more information, visit the company’s website at

Positive ID Corp. (PSID)

Positive ID Corp. (OTCQB: PSID) develops molecular diagnostic systems for bio-threat detection and rapid medical testing. The company focuses on microfluidic systems for the automated preparation of and performance of biological assays for the detection of biological threats at high-value locations and analyzes samples in a medical environment. It has a portfolio of intellectual property related to sample preparation and rapid medical testing applications. For more information, visit the company website at

U.S. Geothermal, Inc. (HTM)

U.S. Geothermal, Inc. (NYSE: HTM) builds, manages and operates power plants that use geothermal resources in the Western United States. The company holds interest in the Raft River project comprising two packages of property covering 6,002 acres, including 1,686 acres of federal geothermal rights and 4,316 acres of private leases located in Idaho; the San Emidio project consisting of geothermal power project, 17,846 acres of geothermal leases and ground water rights used for cooling water located in Nevada; and the Neal Hot Springs, geothermal resource located in Eastern Oregon. For more information, visit the company website at

SLOT 2 – 1:30pm

BioLife Solutions, Inc. (BLFS)

BioLife Solutions, Inc. (NASDAQ: BLFS) develops, manufactures and markets hypothermic storage and cryopreservation solutions and precision thermal shipping products for cells, tissues and organs. The company's proprietary HypoThermosol and CryoStor biopreservation media products are highly valued in the biobanking, drug discovery and regenerative medicine markets. These products are serum-free, protein-free, fully-defined and formulated to reduce preservation-induced cell damage and death. Additionally, the company’s enabling technology provides commercial companies and clinical researchers with significant improvement in the shelf life and post-preservation viability and function of cells, tissues, and organs. For more information, visit the company’s website at

DATATRAK International, Inc. (DTRK)

DATATRAK International, Inc. (OTCQX: DTRK) is a technology and services company that provides eClinical solutions for the clinical trials industry. The company offers DATATRAK ONE clinical research software which is a cloud-based clinical enterprise solution for design, deliver, and management of clinical trials. DTRK also provides uCTMS for planning and managing studies; uDesign for streamlining design-to-deployment process; uEDC to capture and deliver data; uIRT to randomize and manage supplies; uSafety to manage individual case safety reports; uTrain to train users and track certificates; and uPRO for collecting patient-driven data over the Internet. For more information, visit the company website at

HopTo, Inc. (HPTO)

HopTo, Inc. (OTCQB: HPTO) is an innovator of a unique mobile productivity workspace platform. The HopTo mobile solution delivers an unparalleled user experience without compromising enterprise security. HopTo brings a new standard of mobile productivity by enabling individuals to efficiently and effectively search, access, create, edit and share content from their mobile devices by leveraging any combination of on premise or cloud-stored content, documents and data as well as enterprise applications. For more information, visit the company’s website at

Powerstorm Holdings, Inc. (PSTO)

Powerstorm Holdings, Inc. (OTC: PSTO) focuses on developing and providing hybrid energy solutions for the telecommunication infrastructure industry worldwide. The company intends to provide equipment and services for this industry primarily in energy storage and management, base stations, telecommunication towers, and related equipment. Founded in 2011 and based in Rancho Palos Verdes, California, the company was formerly known as Powerstorm Capital Corporation and became Powerstorm Holdings in February 2015. For more information, visit the company’s website at

SLOT 3 – 2pm

NeuroVive Pharmaceutical AB (NEVPF)

NeuroVive Pharmaceutical AB (OTC: NEVPF) is involved in the research and development of mitochondrial-protecting pharmaceuticals in Sweden and Hong Kong. The company’s product portfolio includes its drug candidate CicloMulsion, which is in phase 3 clinical study for cell protection against reperfusion injury during heart attack treatment; NeuroSTAT, a drug candidate that is in phase 2a clinical study for the treatment of traumatic brain injuries; and NVP019, an intravenous formulation that is in pre-clinical phase for treating myocardial infarct and traumatic brain injury. For more information, visit the company’s website at

NovaBay Pharmaceuticals, Inc. (NBY)

NovaBay Pharmaceuticals, Inc. (AMEX: NBY) is a biopharmaceutical company focused on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global topical anti-infective market with its two distinct product categories: the NEUTROX™ Family of Products, including AVENOVA™ for the eye care market and NEUTROPHASE® for wound care, which was initially cleared by the FDA; CELLERX™ for the dermatology market; and its AGANOCIDE® compounds, led by AURICLOSENE™. For more information, visit the company’s website at

SANUWAVE Health, Inc. (SNWV)

SANUWAVE Health, Inc. (OTCQB: SNWV) is a shockwave technology company focused on the development and commercialization of noninvasive, high-energy, and acoustic shockwaves for regenerative medicine and other applications. The company’s shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. For more information, visit the company website at

Viscount Systems, Inc. (VSYS)

Viscount Systems, Inc. (OTC: VSYS) is a software company specializing in physical and logical security solutions. Viscount provides next-gen, IT-centric access control and identity management applications. The company's Freedom application platform allows the seamless unification of the physical and digital security worlds by replacing discrete, self-contained systems with an integrated security system that is sophisticated enough to protect today's critical business assets, and flexible enough to keep up with the evolving IT infrastructures of government and private organizations. For more information, visit the company’s website at

SLOT 4 – 2:30pm

DARA BioSciences, Inc. (DARA)

DARA BioSciences, Inc. (NASDAQ: DARA) of Raleigh, North Carolina, is an oncology supportive care pharmaceutical company dedicated to providing health care professionals a portfolio of medicines to help cancer patients stick to their therapy and manage side effects arising from their cancer treatment. DARA holds exclusive U.S. marketing rights to the Soltamox (tamoxifen citrate) oral solution, Gelclair oral rinse gel, and Oravig (miconazole). For more information, visit the company’s website at

Direct Insite Corp. (DIRI)

Direct Insite Corp. (OTCQB: DIRI) provides a powerful platform for unified working capital management that facilitates more than $160 billion worth of transactions annually between more than 375,000 companies worldwide. Its clients include IBM, Hewlett-Packard, Siemens, BE Aerospace, Saint Gobain and Carlson. The flagship component of Direct Insite's unified working capital management platform is PAYBOX, an integrated receivables solution that combines electronic invoicing, online approvals and adjustments, electronic payments and integration with any legacy accounting, ERP or lockbox system. For more information, visit the company’s website at

Interleukin Genetics, Inc. (ILIU)

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health-related conditions. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The company markets its tests through partnerships with health and wellness companies, healthcare professionals, and other distribution channels. For more information, visit

Nephros, Inc. (NEPH)

Nephros, Inc. (OTCBB: NEPH), a commercial stage medical device company, develops and sells high-performance liquid purification ultra-filters and an online mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of patients with end stage renal disease. Its ultra-filters are primarily used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate and/or blood. Nephros was founded in 1997 by healthcare professionals affiliated with Columbia University Medical Center/New York-Presbyterian Hospital to develop and commercialize a hemodiafiltration system, an alternative method to hemodialysis. For more information, visit the company’s website at

Nuvel Holdings, Inc. (NUVL)

Nuvel Holdings, Inc. (OTC: NUVL) designs, develops and sells a family of appliances, software and services that secure, accelerate and optimize the delivery of business applications, web content, and other information to distributed users over a wide area network (WAN) or across an enterprise’s gateway to the public Internet. The company’s products provide end-user customers with information about the applications and Web traffic running on their networks. For more information, visit the company’s website at

RiceBran Technologies (RIBT)

RiceBran Technologies (NASDAQ: RIBT) is a global leader in the production and marketing of value-added products derived from rice bran. The company has proprietary and patented intellectual property that allows it to convert rice bran, one of the world's most underutilized food sources, into a number of highly nutritious human food ingredient and animal nutrition products. Its target markets are human food ingredients and animal nutrition manufacturers and retailers, as well as natural food, functional food and nutritional supplement manufacturers and retailers, both domestically and internationally. For more information, visit the company’s website at

RXi Pharmaceuticals Corp. (RXII)

RXi Pharmaceuticals Corp. (NASDAQ: RXII), a biotechnology company, is focused on discovering and developing innovative therapeutics that address high-unmet medical needs, primarily in the area of dermatology and ophthalmology. Its discovery and clinical development programs are based on siRNA technology as well as immunotherapy agents, and includes its proprietary, self-delivering RNAi (sd-rxRNA) compounds for the treatment of dermal and retinal scarring. It also includes an immunomodulator, Samcyprone, a proprietary topical formulation of diphenylcyclopropenone (DPCP) for the treatment of such disorders as alopecia areata, warts and cutaneous metastases of melanoma. For more information, visit the company’s website at

SLOT 5 – 3pm

Avant Diagnostics (AVDX)

Avant Diagnostics (OTCBB: AVDX) is a diagnostic company mainly focused on the commercialization of OvaDx, a proprietary microarray-based diagnostic test for the early detection of ovarian cancer. Pre-clinical research studies with OvaDx indicate high sensitivity and specificity for all types and stages of ovarian cancer. Upon FDA 510K approval, Avant Diagnostics intends to sell or license OvaDx as a diagnostic test for women seeking greater wellness and for women in the elevated risk category for ovarian cancer. Avant intends to utilize its public company stage to expand its portfolio of diagnostic tests in the future. For more information, visit the company’s website at

Inventergy Global, Inc. (INVT)

Inventergy Global, Inc. (NASDAQ: INVT) is an intellectual property (IP) investment and licensing company. The company identifies, acquires and licenses the patented technologies of technology companies. INVT offers a professional corporate licensing model for IP value creation that provides short term returns and long-term licensing revenue. The company acquires portfolios in the telecom sector, primarily in IP multimedia subsystems, and VoIP and mobile broadband communications segments. For more information, visit the company website at

Sanomedics, Inc. (SIMH)

Sanomedics, Inc. (OTC: SIMH) is an international medical technology company focused on developing, manufacturing and acquiring technology, products and services through its subsidiary, Thermomedics, which is dedicated to engineering, marketing and selling the Caregiver TouchFree Infrared thermometer. The thermometer is FDA-cleared in the U.S. for clinical use and provides an accurate, expedited temperature reading without direct contact between the patient and medical professional. Sanomedics has established a wide distribution network with several leading healthcare supply chain providers to increase adoption of the Caregiver device within the medical community worldwide. For more information, visit the company’s website at

VirtualScopics, Inc. (VSCP)

VirtualScopics, Inc. (NASDAQ: VSCP) provides clinical trial imaging solutions that are meant to accelerate drug and medical device development. For risk-averse, time-constrained clinical trial study teams, medical directors and imaging scientists who require quality imaging data delivered on-time, within budget, and on a consistent basis, VirtualScopics' clinical trial imaging solutions are inspired choices. Because of the scientific and operational flexibility and responsiveness available, VirtualScopics' clinical trial imaging solutions deliver special performance advantages compared to other image service providers that offer common, every day clinical trial imaging services. For more information, visit the company’s website at

SLOT 6 – 3:30pm

Anavex Life Sciences Corp. (AVXL)

Anavex Life Sciences Corp. (OTCQX: AVXL) is dedicated to the development of novel drug candidates to treat central nervous system (CNS) diseases, pain and various types of cancer. The company's lead drug candidates, ANAVEX 2-73 and ANAVEX PLUS, are currently being evaluated in a phase 2a clinical trial for Alzheimer's disease. ANAVEX 2-73 has successfully completed a phase 1 study with a clean data profile. Preclinical studies demonstrate its potential to halt and/or reverse the course of Alzheimer's disease. The drug combination, ANAVEX PLUS, produced up to 80% greater reversal of memory loss in Alzheimer's disease models versus when the drugs were used individually. For more information, visit the company’s website at

Immune Pharmaceuticals, Inc. (IMNP)

Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) applies a personalized approach to treating and developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The company's lead product candidate, bertilimumab, is in clinical development for moderate to severe ulcerative colitis and Crohn's disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition. Immune's pipeline also includes NanomAbs, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics, and AmiKet, a neuropathic pain drug candidate ready for a phase 3 clinical trial. For more information, visit the company’s website at

Lomiko Metals, Inc. (LMRMF)

Lomiko Metals, Inc. (OTCQX: LMRMF) is involved in the acquisition, exploration and development of mineral resource properties in Canada, but primarily explores for graphite deposits. Its principal properties include the Vines Lake property located in British Columbia; and the Quatre Milles West and Quatre Milles East properties located in Quebec. Originally incorporated in 1987, the company’s headquarters are in Surrey, Canada. For more information, visit the company’s website at

Milestone Scientific, Inc. (MLSS)

Milestone Scientific, Inc. (OTC: MLSS) delivers technology-based solutions for the medical and dental markets in the United States, Canada, Asia, Africa, South America and Europe. Company products include STA Single Tooth Anesthesia Instrument, a computer-controlled local anesthesia delivery instrument that incorporates the pressure feedback elements of its patented CompuFlo technology CompuDent, which is a computer-controlled local anesthetic delivery instrument that provides painless injections for routine dental treatments. For more information visit the company website at

True Drinks Holdings, Inc. (TRUU)

True Drinks Holdings, Inc. (OTC: TRUU) is a healthy beverage provider with licensing agreements with Disney and Marvel for use of their characters on its proprietary, patented bottles. The company is the maker of AquaBall, a naturally flavored, vitamin-enhanced, zero-calorie, dye-free and sugar-free alternative to juice and soda that is currently available in four flavors: orange, grape, fruit punch and berry. The company’s target consumers -- kids, young adults and their guardians – are particularly attracted to the product because of the entertainment and media characters on the bottle but continue to consume the beverage because of its health benefits and great taste. For more information, visit the company’s website at

SLOT 7 – 4pm

GeoVax Labs, Inc. (GOVX)

GeoVax Labs, Inc. (OTCQB: GOVX) is a clinical-stage biotechnology company focused on developing human vaccines that fight infectious diseases using its novel vaccine platform. The company centers its attention on developing vaccines against Ebola and Marburg viruses, and human immunodeficiency virus (HIV). Its vaccines under development include GOVX-B11 and GOVX-B21 vaccines that are in phase 2a clinical trials to treat clade B subtype of HIV virus; and in preclinical research to treat clade C subtype of HIV virus. Founded in 2001, the company is based in Smyrna, Georgia. For more information visit the company website at

Greenwood Hall, Inc. (ELRN)

Greenwood Hall, Inc. (OTCQB: ELRN) provides cloud-based education management services to public and not-for-profit higher education institutions in the U.S. It also offers solutions that support the student lifecycle, including lead generation/marketing, new student recruitment, enrollment counseling, financial aid advising, new student recruitment, retention counseling, career advising, student concierge, and help desk services. For more information visit the company website at, Inc. (HEWA), Inc. (OTCQB: HEWA) is a trusted VIPPS-accredited online pharmacy based in Florence, Kentucky. The company is focused on the growing out-of-pocket prescription market, which is expected to grow to $80 billion in 2015. With a mission to provide affordable healthcare to every American by focusing on technology that is revolutionizing prescription delivery, has become the largest VIPPS-accredited online pharmacy in the United States. It is licensed in all 50 states and only sells drugs that are FDA-approved and legal for sale in the United States. For more information, visit the company’s website at

Mantra Venture Group Ltd. (MVTG)

Mantra Venture Group Ltd. (OTCQB: MVTG) is a clean technology incubator that takes innovative emerging technologies and moves them toward commercialization. The company, through its subsidiary Mantra Energy Alternatives, is currently developing two groundbreaking electrochemical technologies designed to make reducing greenhouse gas emissions profitable, ERC (Electro-Reduction of Carbon Dioxide) and MRFC (Mixed-Reactant Fuel Cell). For more information, visit the company’s website at

SG Blocks, Inc. (SGBX)

SG Blocks, Inc. (OTC: SGBX) is focused on advancing and promoting the use of code-engineered cargo shipping containers for safe and sustainable construction. The firm offers a product that exceeds many standard building code requirements, and also supports developers, architects, builders and owners in achieving greener construction, faster execution, and stronger buildings of higher value. It has four product lines: retail, commercial, military and residential. SG Blocks also has an exclusive 10-year collaboration and supply contract with ConGlobal Industries Inc., the largest shipping container depot operator in the United States. For more information, visit the company’s website at


For more frequent updates, follow us on Twitter!

Home     About Us     Blog     Investors     IR Services     Market Research     Partners     Contact     Disclaimer

© 2013 Mission Investor Relations. All rights reserved.
3645 Marketplace Blvd.   Suite 130-280   Atlanta, GA 30344   404-941-8975